Methods for treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-CD3 antibodies alone or in combination with an anti-PD-1 antibody
JP2025517336A5Pending Publication Date: 2026-05-22REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- REGENERON PHARMACEUTICALS INC
- Filing Date
- 2023-05-15
- Publication Date
- 2026-05-22
AI Technical Summary
Technical Problem
Current treatments for prostate cancer, particularly castration-resistant prostate cancer, are limited in effectiveness and often associated with toxicity, necessitating the development of new therapeutic approaches.
Method used
Administration of a bispecific antibody that specifically binds to prostate-specific membrane antigen (PSMA) and CD3, alone or in combination with an antibody that binds to programmed death 1 (PD-1), to enhance immune activation and targeting of cancer cells.
Benefits of technology
The bispecific antibody therapy demonstrates potential in slowing tumor growth, preventing recurrence, and improving survival in patients with PSMA-expressing cancers, including prostate cancer, by activating T cells and enhancing immune response.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
The present disclosure provides methods for treating, reducing the severity of, or inhibiting the growth of cancer (e.g., prostate cancer or metastatic castration-resistant prostate cancer). The methods of the disclosure include administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody that specifically binds prostate-specific membrane antigen (PSMA) and CD3, or an antigen-binding fragment thereof, alone or in combination with an antibody that specifically binds to the Programmed death 1 (PD-1) receptor, or an antigen-binding fragment thereof.
Need to check novelty before this filing date? Find Prior Art